- About
- Organization
- Organization Overview
- Dean’s Office
- Department of Bioengineering and Therapeutic Sciences
- Department of Clinical Pharmacy
- Department of Pharmaceutical Chemistry
- Quantitative Biosciences Institute
- Org Chart
- Research
- Education
- Patient Care
- People
- News
- Events
Industry data should be shared
By UCSF School of Pharmacy Editorial Staff / Thu Jul 28, 2005
The same level of legal scrutiny that applies to research funded by the US government should apply to research funded by industry, according to UCSF School of Pharmacy faculty member Lisa Bero, PhD, and co-authors of a study that appeared July 20, 2005 in the online issue of American Journal of Public Health.
Laws passed by the US Congress in 1998 and 2001 require that raw data from federally funded research be available to the public for review and follow specific quality standards. No such laws govern industry-sponsored research, says Bero. "As a result, the public health community cannot use (these laws) to challenge industry science," she explains. The scientific community should support efforts "…to make privately sponsored health and safety testing data available to scientists for interpretation and analysis," conclude the co-authors.
More
Unprecedented Industry-backed Laws Limit Public Safety, Study Shows
Tags
Keywords:
Category:
Sites:
School of Pharmacy, Department of Clinical Pharmacy, PharmD Degree Program
About the School: The UCSF School of Pharmacy aims to solve the most pressing health care problems and strives to ensure that each patient receives the safest, most effective treatments. Our discoveries seed the development of novel therapies, and our researchers consistently lead the nation in NIH funding. The School’s doctor of pharmacy (PharmD) degree program, with its unique emphasis on scientific thinking, prepares students to be critical thinkers and leaders in their field.
Related news
- Analysis finds sponsorship biases in animal studies may differ from those in clinical trials
- New review finds drug, device study results affected by funding source
- The Lancet profiles Lisa Bero’s “path of most resistance”
- Conflicts of interest significantly underreported in systematic reviews of drug efficacy, safety
- Industry-sponsored research more likely to favor drug than placebo
